Skip to main content

SpeciCare Revolutionizes Gene Mapping

SpeciCare Revolutionizes Cancer Treatment with Tumor Cryopreservation and Gene Mapping


SpeciCare cryopreserves tumor tissue, enabling expanded therapy testing and empowering patients with personalized, future-ready treatment opportunities.

GAINESVILLE, GA, UNITED STATES, March 17, 2025 /EINPresswire.com/ -- SpeciCare, a pioneering healthcare company, is transforming cancer treatment by offering patients the ability to cryopreserve their tumor tissue for advanced genomic assays and more specific personalized therapies. Founded by a group of oncology specialists and advanced clinical researchers, SpeciCare aims to move beyond traditionally mass-administered cancer treatments to provide more effective individualized cancer care.

For decades, cancer treatment has relied on outdated tumor storage methods that provide limited views of the affected tissue—like trying to solve a city’s traffic crisis using a single aerial snapshot. But what if researchers had a live traffic feed instead? That’s what cryopreserving tumor tissue offers—an evolving, real-time window into cancer’s behavior, which is currently the missing component in bringing precision oncology care to the individual cancer patient.

By cryopreserving live tumor tissue, SpeciCare enables comprehensive genomic assays, which is not possible with the current FFPE method that destroys testable tissue. This necessary modification in the way that tissue is preserved and stored facilitates the development of tailored treatment plans for each patient. This individualized approach increases the efficacy of therapies and minimizes unnecessary side effects, offering patients a more targeted and effective treatment journey.

Access to their own cryopreserved tissue with Specicare allows patients to participate in multiple clinical trials simultaneously, without the need for additional surgeries or invasive procedures. This accessibility not only broadens treatment options but also accelerates the discovery of new therapies, benefiting not only the individual patient, but the broader cancer community as well.

The rise in cord blood banking popularity has highlighted the benefits of preserving personal biologics for future medical use. Similarly, tumor cryopreservation offers patients the opportunity to safeguard their unique cancer profile, ensuring access to cutting-edge treatments as they become available without added invasive procedures to acquire new tissue.

The time is right for the adoption of this much-improved method of tumor tissue management with the explosive addition of Artificial Intelligence (AI) to the healthcare space and specifically in the area of genomic assays. The union of Specicare’s access to the consented patient, the electronic medical record and the pristine tumor specimen is central to bringing AI successfully into the oncologic treatment arena.

The window between the initial suspicion of cancer and the biopsy is often narrow, making early intervention crucial. SpeciCare emphasizes the importance of involving preservation services as soon as cancer is suspected, ensuring that collection kits are available to surgeons before the biopsy. SpeciCare is committed to making advanced cancer treatments accessible to the individual patient and his or her family, with initial costs under $500. This affordability ensures that more patients can benefit from personalized therapies without financial strain.

Dr. Ken Dixon founded SpeciCare out of a desire to offer more to his patients. Frustrated with the limitations of traditional treatments, he envisioned a future where patients have control over their tumor tissue, unlocking new avenues for personalized care and improved outcomes.

Gene mapping, genetic markers, genome sequencing, linkage analysis, association mapping, quantitative trait loci (QTL), SNP genotyping, whole genome sequencing, genetic variation, gene localization, recombination frequency, chromosomal mapping, DNA sequencing, functional genomics, positional cloning, genetic linkage, genetic mapping techniques, molecular markers, bioinformatics in gene mapping, next-generation sequencing (NGS),

#GeneMapping, #GeneticMarkers, #GenomeSequencing, #LinkageAnalysis, #AssociationMapping, #QTL, #SNPGenotyping, #WholeGenomeSequencing, #GeneticVariation, #GeneLocalization, #RecombinationFrequency, #ChromosomalMapping, #DNASequencing, #FunctionalGenomics, #PositionalCloning, #GeneticLinkage, #MolecularMarkers, #Bioinformatics, #NextGenSequencing, #GenomicsResearch

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Genetics role in ovarian cancer

The Medical Minute: Genetics play big role in ovarian cancer In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die from the disease, said Dr. Shaina Bruce , a gynecologic oncologist at Penn State Cancer Institute . The median age of all patients who develop ovarian cancer is 63. Historically, women at increased risk for ovarian cancer are recommended to have their fallopian tubes and ovaries removed when they have completed having children. Taking that step to protect themselves comes at a heavy price ― surgical menopause. But Bruce said medical science is catching up with ovarian cancer. Studies could lead to new methods for preventative care and the surgery needed to lower risk may be easier than it once was. Below, during Gynecologic Cancer Awareness Month, Bruce discusses the disease and why acting to reduce your risk is worth it. What’s the connection between heredity and ovarian cancer? About 25% of all cases of ...
Post a Comment
Read more

Multifactorial Genetic Conditions

Multifactorial Genetic Conditions Multifactorial genetic conditions are disorders caused by the combined effects of multiple genes and environmental factors , rather than a single gene mutation . These conditions do not follow classic Mendelian inheritance patterns and instead result from complex gene–environment interactions . Factors such as lifestyle, nutrition, infections, stress, and exposure to toxins can significantly influence disease onset and severity in genetically susceptible individuals. Common examples include diabetes, cardiovascular diseases , neural tube defects, asthma, and many neuropsychiatric disorders. Understanding multifactorial inheritance is essential for risk prediction, preventive medicine, and personalized healthcare strategies. Multifactorial inheritance, polygenic traits, gene–environment interaction, complex diseases, genetic susceptibility, environmental risk factors, non-Mendelian inheritance, disease predisposition, polygenic risk score, precision ...
Post a Comment
Read more

X chromosome

Gene on the X chromosome may help explain high multiple sclerosis rates in women Brain inflammation may be fueled by a gene on the X chromosome, a new study in mice suggests. And in female mice, who carry two X chromosomes, a diabetes drug called metformin may work to counteract that inflammation. If these findings bear out in later studies, they could help to unravel the long-standing mystery of why women, who have two copies of this inflammation-driving gene, are more prone to certain autoimmune diseases, particularly after menopause. A disparity between the sexes Our bodies are patrolled by immune cells that provide protection against bacteria and viruses, but sometimes, these defenses turn on us. In the autoimmune disorder multiple sclerosis (MS), for instance, the immune system attacks myelin, the fatty insulation surrounding the nerve fibers in the brain and spinal cord. This leads to symptoms such as muscle weakness and difficulty walking, as well issues with memory and thinking...
Post a Comment
Read more